Phase 1 clinical trial evaluating the safety, tolerability, and preliminary efficacy of intrathecal injection of ACP-01 in subjects who suffer from vascular dementia
Latest Information Update: 07 Mar 2025
At a glance
- Drugs ACP 01 (Primary)
- Indications Vascular dementia
- Focus Adverse reactions
- Sponsors Hemostemix
Most Recent Events
- 07 Mar 2025 New trial record
- 06 Mar 2025 According to Hemostemix media release, clinical evidence supports the use of Firefly FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia